Tonix to Present 95% Efficacy TNX-4800 Data and TNX-801 Vaccine Studies
Tonix will present Phase 1 data on TNX-4800, a long-acting anti-Borrelia OspA monoclonal antibody showing 95% animal efficacy and serum levels quantifiable for up to 350 days. The company will also showcase preclinical TNX-801 horsepox vaccine studies and a modular antigen-delivery panel at the April conference sessions.
1. World Vaccine Congress Schedule
Tonix will deliver three sessions at the World Vaccine Congress Washington from March 30 to April 1, 2026: an oral presentation on Phase 1 TNX-4800 data on March 30, an animal and in vitro study on TNX-801 on April 1 morning, and a panel on modular antigen-delivery systems on April 1 afternoon.
2. TNX-4800 Phase 1 Data and Preclinical Profile
TNX-4800 is a long-acting human monoclonal antibody targeting Borrelia burgdorferi OspA, showing 95% efficacy in animal challenge studies and engineered Fc modifications that produced serum concentrations quantifiable for up to 350 days and mean half-lives of 62-69 days across dose cohorts in Phase 1 safety and pharmacokinetic evaluations. Tonix plans to have GMP material ready for clinical trials in early 2027, with a field study expected in H1 2027 and a controlled human infection model study in 2028.
3. TNX-801 and Antigen-Delivery Panel
TNX-801 is an attenuated horsepox-based vaccine candidate in pre-IND development for smallpox and mpox prevention, with a planned Phase 1 study in 2027 pending FDA clearance. Tonix’s virology director will present the live virus vaccine data, and the immunology director will moderate a discussion on poxvirus modular antigen-delivery systems for novel broad immunity vaccines.